Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity

被引：748

作者：

Siegal, Deborah M. ^{[1
]}

Curnutte, John T. ^{[3
]}

Connolly, Stuart J. ^{[1
,2
]}

Lu, Genmin ^{[3
]}

Conley, Pamela B. ^{[3
]}

Wiens, Brian L. ^{[3
]}

Mathur, Vandana S. ^{[4
]}

Castillo, Janice ^{[3
]}

Bronson, Michele D. ^{[3
]}

Leeds, Janet M. ^{[3
]}

Mar, Florie A. ^{[3
]}

Gold, Alex ^{[3
]}

Crowther, Mark A. ^{[1
]}

机构：

[1] McMaster Univ, Hamilton, ON L8N 4A6, Canada

[2] Populat Hlth Res Inst, Hamilton, ON, Canada

[3] Portola Pharmaceut, San Francisco, CA USA

[4] Mathur Consulting, Woodside, CA USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2015年 / 373卷 / 25期

关键词：

ATRIAL-FIBRILLATION; WARFARIN; MANAGEMENT; APIXABAN;

D O I：

10.1056/NEJMoa1510991

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BACKGROUND Bleeding is a complication of treatment with factor Xa inhibitors, but there are no specific agents for the reversal of the effects of these drugs. Andexanet is designed to reverse the anticoagulant effects of factor Xa inhibitors. METHODS Healthy older volunteers were given 5 mg of apixaban twice daily or 20 mg of rivaroxaban daily. For each factor Xa inhibitor, a two-part randomized placebo-controlled study was conducted to evaluate andexanet administered as a bolus or as a bolus plus a 2-hour infusion. The primary outcome was the mean percent change in anti-factor Xa activity, which is a measure of factor Xa inhibition by the anticoagulant. RESULTS Among the apixaban-treated participants, anti-factor Xa activity was reduced by 94% among those who received an andexanet bolus (24 participants), as compared with 21% among those who received placebo (9 participants) (P<0.001), and un-bound apixaban concentration was reduced by 9.3 ng per milliliter versus 1.9 ng per milliliter (P<0.001); thrombin generation was fully restored in 100% versus 11% of the participants (P<0.001) within 2 to 5 minutes. Among the rivaroxaban-treated participants, anti-factor Xa activity was reduced by 92% among those who received an andexanet bolus (27 participants), as compared with 18% among those who received placebo (14 participants) (P<0.001), and unbound rivaroxaban concentration was reduced by 23.4 ng per milliliter versus 4.2 ng per milliliter (P<0.001); thrombin generation was fully restored in 96% versus 7% of the participants (P<0.001). These effects were sustained when andexanet was administered as a bolus plus an infusion. In a subgroup of participants, transient increases in levels of d-dimer and prothrombin fragments 1 and 2 were observed, which resolved within 24 to 72 hours. No serious adverse or thrombotic events were reported. CONCLUSIONS Andexanet reversed the anticoagulant activity of apixaban and rivaroxaban in older healthy participants within minutes after administration and for the duration of infusion, without evidence of clinical toxic effects.

引用

页码：2413 / 2424

页数：12

共 26 条

[11] Edoxaban versus Warfarin in Patients with Atrial Fibrillation [J].

Giugliano, Robert P. ;

Ruff, Christian T. ;

Braunwald, Eugene ;

Murphy, Sabina A. ;

Wiviott, Stephen D. ;

Halperin, Jonathan L. ;

Waldo, Albert L. ;

Ezekowitz, Michael D. ;

Weitz, Jeffrey I. ;

Spinar, Jindrich ;

Ruzyllo, Witold ;

Ruda, Mikhail ;

Koretsune, Yukihiro ;

Betcher, Joshua ;

Shi, Minggao ;

Grip, Laura T. ;

Patel, Shirali P. ;

Patel, Indravadan ;

Hanyok, James J. ;

Mercuri, Michele ;

Vogelmann, O. ;

Gonzalez, C. ;

Ahuad Guerrero, R. ;

Rodriguez, M. ;

Albisu, J. ;

Rosales, E. ;

Allall, O. ;

Reguero, M. ;

Alvarez, C. ;

Garcia, M. ;

Ameriso, S. ;

Ameriso, P. ;

Amuchastegui, M. ;

Caceres, M. ;

Beloscar, J. ;

Petrucci, J. ;

Berli, M. ;

Budassi, N. ;

Valle, M. ;

Bustamante Labarta, G. ;

Saravia, M. ;

Caccavo, A. ;

Fracaro, V. ;

Cartasegna, L. ;

Novas, V. ;

Caruso, O. ;

Saa Zarandon, R. ;

Colombo, H. ;

Morandini, M. ;

Cuello, J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (22) :2093-2104

[12] Apixaban versus Warfarin in Patients with Atrial Fibrillation [J].

Granger, Christopher B. ;

Alexander, John H. ;

McMurray, John J. V. ;

Lopes, Renato D. ;

Hylek, Elaine M. ;

Hanna, Michael ;

Al-Khalidi, Hussein R. ;

Ansell, Jack ;

Atar, Dan ;

Avezum, Alvaro ;

Cecilia Bahit, M. ;

Diaz, Rafael ;

Easton, J. Donald ;

Ezekowitz, Justin A. ;

Flaker, Greg ;

Garcia, David ;

Geraldes, Margarida ;

Gersh, Bernard J. ;

Golitsyn, Sergey ;

Goto, Shinya ;

Hermosillo, Antonio G. ;

Hohnloser, Stefan H. ;

Horowitz, John ;

Mohan, Puneet ;

Jansky, Petr ;

Lewis, Basil S. ;

Luis Lopez-Sendon, Jose ;

Pais, Prem ;

Parkhomenko, Alexander ;

Verheugt, Freek W. A. ;

Zhu, Jun ;

Wallentin, Lars .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (11) :981-992

[13] Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial [J].

Held, Claes ;

Hylek, Elaine M. ;

Alexander, John H. ;

Hanna, Michael ;

Lopes, Renato D. ;

Wojdyla, Daniel M. ;

Thomas, Laine ;

Al-Khalidi, Hussein ;

Alings, Marco ;

Xavier, Dennis ;

Ansell, Jack ;

Goto, Shinya ;

Ruzyllo, Witold ;

Rosenqvist, Marten ;

Verheugt, Freek W. A. ;

Zhu, Jun ;

Granger, Christopher B. ;

Wallentin, Lars .

EUROPEAN HEART JOURNAL, 2015, 36 (20) :1264-1272

[14]

Hollenbach S, 2012, 54 ANN M AM SOC HEM

[15]

Hollenbach S, 2012, EUR SOC CARD C MUN G

[16] A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa [J].

Lu, Genmin ;

DeGuzman, Francis R. ;

Hollenbach, Stanley J. ;

Karbarz, Mark J. ;

Abe, Keith ;

Lee, Gail ;

Luan, Peng ;

Hutchaleelaha, Athiwat ;

Inagaki, Mayuko ;

Conley, Pamela B. ;

Phillips, David R. ;

Sinha, Uma .

NATURE MEDICINE, 2013, 19 (04) :446-+

[17]

Lu GM, 2010, CIRCULATION, V122

[18] Changes in molecular markers of hemostatic and fibrinolytic activation under various sampling conditions using vacuum tube samples from healthy volunteers [J].

Omote, Mika ;

Asakura, Hidesaku ;

Takamichi, Sayuri ;

Shibayama, Masami ;

Yoshida, Tomotaka ;

Kadohira, Yasuko ;

Maekawa, Mio ;

Yamazaki, Masahide ;

Morishita, Eriko ;

Nakao, Shinji ;

Wada, Takashi .

THROMBOSIS RESEARCH, 2008, 123 (02) :390-395

[19] Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation [J].

Patel, Manesh R. ;

Mahaffey, Kenneth W. ;

Garg, Jyotsna ;

Pan, Guohua ;

Singer, Daniel E. ;

Hacke, Werner ;

Breithardt, Guenter ;

Halperin, Jonathan L. ;

Hankey, Graeme J. ;

Piccini, Jonathan P. ;

Becker, Richard C. ;

Nessel, Christopher C. ;

Paolini, John F. ;

Berkowitz, Scott D. ;

Fox, Keith A. A. ;

Califf, Robert M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (10) :883-891

[20] Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: Proposals of the Working Group on Perioperative Haemostasis (GIHP) - March 2013 [J].

Pernod, Gilles ;

Albaladejo, Pierre ;

Godier, Anne ;

Samama, Charles M. ;

Susen, Sophie ;

Gruel, Yves ;

Blais, Normand ;

Fontana, Pierre ;

Cohen, Ariel ;

Llau, Juan V. ;

Rosencher, Nadia ;

Schved, Jean-Francois ;

de Maistre, Emmanuel ;

Samama, Meyer M. ;

Mismetti, Patrick ;

Sie, Pierre .

ARCHIVES OF CARDIOVASCULAR DISEASES, 2013, 106 (6-7) :382-393

← 1 2 3 →